MYOC and open-angle glaucoma: A non-randomized interventional trial of a BD113 virus-like particle, a lentiviral-based CRISPR-Cas9 gene therapy targeted to knock down MYOC, has commenced recruitment of adults with myocilin-related POAG refractory to initial treatment and will primarily assess IOP reduction following a single intracameral injection [137].